FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 339:380-386 August 6, 1998 Number 6 Next

	Full Text PDF Editorial by Detsky, A. S. Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Roizen, M. F. PubMed Citation

ABSTRACT

Background The gain in life expectancy is an important measure of the effectiveness of medical interventions, but its interpretation requires that it be placed in context. The interpretation of gains in life expectancy is particularly problematic for preventive interventions, for which the gains are often just weeks or even days when averaged across the entire target population.

Methods We tabulated the gains in life expectancy from a variety of medical interventions as reported in 83 published sources and categorized them according to target population and disease. We considered prevention in populations at average risk for particular diseases, prevention in populations at elevated risk, and treatments in populations with established disease.

Results The gains in life expectancy from preventive interventions in populations at average risk ranged from less than one month to slightly more than one year per person receiving the intervention, but the gains were as high as five years or more if the prevention was targeted at persons at especially high risk. The gains in life expectancy from treatments of established disease ranged from several months (for coronary thrombolysis and revascularization to treat heart disease) to as long as nine years (for chemotherapy to treat advanced testicular cancer).

Conclusions A gain in life expectancy from a medical intervention can be categorized as large or small by comparing it with gains from other interventions aimed at the same target population. A gain in life expectancy of a month from a preventive intervention targeted at populations at average risk and a gain of a year from a preventive intervention targeted at populations at elevated risk can both be considered large. The framework we developed for standardizing gains in life expectancy can be used in the interpretation of data on the outcomes of interventions.

Source Information

From the Harvard School of Public Health, Boston.

Address reprint requests to Dr. Weinstein at the Department of Health Policy and Management, Harvard School of Public Health, 718 Huntington Ave., Boston, MA 02115.

Full Text of this Article

Related Letters:

Gains in Life Expectancy from Medical Interventions
Roizen M. F., Roach K., Messori A., Trippoli S., Tendi E., Weinstein M. C., Wright J. C.
Extract | Full Text  
N Engl J Med 1998; 339:1943-1944, Dec 24, 1998. Correspondence

This article has been cited by other articles:

• Nelson, A. L., Cohen, J. T., Greenberg, D., Kent, D. M. (2009). Much Cheaper, Almost as Good: Decrementally Cost-Effective Medical Innovation. ANN INTERN MED 151: 662-667 [Abstract] [Full Text]  
• Gupta, S., Faughnan, M. E., Bayoumi, A. M. (2009). Embolization for Pulmonary Arteriovenous Malformation in Hereditary Hemorrhagic Telangiectasia: A Decision Analysis. Chest 136: 849-858 [Abstract] [Full Text]  
• Dotan, Y., Pinchuk, I., Lichtenberg, D., Leshno, M. (2009). Decision Analysis Supports the Paradigm That Indiscriminate Supplementation of Vitamin E Does More Harm than Good. Arterioscler. Thromb. Vasc. Bio. 29: 1304-1309 [Abstract] [Full Text]  
• Leal, J., Gray, A. M., Clarke, P. M. (2009). Development of life-expectancy tables for people with type 2 diabetes. Eur Heart J 30: 834-839 [Abstract] [Full Text]  
• Rietbrock, S., Olson, M., van Staa, T.P. (2009). The potential effects on fracture outcomes of improvements in persistence and compliance with bisphosphonates. QJM 102: 35-42 [Abstract] [Full Text]  
• Choi, H., Sell, R. L., Lenert, L., Muennig, P., Goodman, R. R., Gilliam, F. G., Wong, J. B. (2008). Epilepsy Surgery for Pharmacoresistant Temporal Lobe Epilepsy: A Decision Analysis. JAMA 300: 2497-2505 [Abstract] [Full Text]  
• Stout, N. K., Goldhaber-Fiebert, J. D., Ortendahl, J. D., Goldie, S. J. (2008). Trade-offs in Cervical Cancer Prevention: Balancing Benefits and Risks. Arch Intern Med 168: 1881-1889 [Abstract] [Full Text]  
• Llovet, J. M., Di Bisceglie, A. M., Bruix, J., Kramer, B. S., Lencioni, R., Zhu, A. X., Sherman, M., Schwartz, M., Lotze, M., Talwalkar, J., Gores, G. J., for the Panel of Experts in HCC-Design Clinical Tr, (2008). Design and Endpoints of Clinical Trials in Hepatocellular Carcinoma. JNCI J Natl Cancer Inst 100: 698-711 [Abstract] [Full Text]  
• van Staa, T P, Smeeth, L, Persson, I, Parkinson, J, Leufkens, H G M (2008). What is the harm-benefit ratio of Cox-2 inhibitors?. Int J Epidemiol 37: 405-413 [Abstract] [Full Text]  
• Nexoe, J., Halvorsen, P. A., Kristiansen, I. S. (2007). Review Article: Critiques of the risk concept -- valid or not?. Scand J Public Health 35: 648-654 [Abstract]  
• Detsky, A. S., Laupacis, A. (2007). Relevance of Cost-effectiveness Analysis to Clinicians and Policy Makers. JAMA 298: 221-224 [Full Text]  
• Losina, E., Walensky, R. P., Geller, A., Beddingfield, F. C. III, Wolf, L. L., Gilchrest, B. A., Freedberg, K. A. (2007). Visual Screening for Malignant Melanoma: A Cost-effectiveness Analysis. Arch Dermatol 143: 21-28 [Abstract] [Full Text]  
• Goldie, S. J., Yazdanpanah, Y., Losina, E., Weinstein, M. C., Anglaret, X., Walensky, R. P., Hsu, H. E., Kimmel, A., Holmes, C., Kaplan, J. E., Freedberg, K. A. (2006). Cost-Effectiveness of HIV Treatment in Resource-Poor Settings -- The Case of Cote d'Ivoire. NEJM 355: 1141-1153 [Abstract] [Full Text]  
• Stout, N. K., Rosenberg, M. A., Trentham-Dietz, A., Smith, M. A., Robinson, S. M., Fryback, D. G. (2006). Retrospective cost-effectiveness analysis of screening mammography.. JNCI J Natl Cancer Inst 98: 774-782 [Abstract] [Full Text]  
• Das, P., Ng, A. K., Earle, C. C., Mauch, P. M., Kuntz, K. M. (2006). Computed tomography screening for lung cancer in Hodgkin's lymphoma survivors: decision analysis and cost-effectiveness analysis. Ann Oncol 17: 785-793 [Abstract] [Full Text]  
• Viscomi, S., Pastore, G., Dama, E., Zuccolo, L., Pearce, N., Merletti, F., Magnani, C. (2006). Life expectancy as an indicator of outcome in follow-up of population-based cancer registries: the example of childhood leukemia. Ann Oncol 17: 167-171 [Abstract] [Full Text]  
• Palmer, A. J., Tucker, D. M. D., Valentine, W. J., Roze, S., Gabriel, S., Cordonnier, D. J. (2005). Cost-effectiveness of irbesartan in diabetic nephropathy: a systematic review of published studies. Nephrol Dial Transplant 20: 1103-1109 [Abstract] [Full Text]  
• Lotan, Y., Cadeddu, J. A., Lee, J. J., Roehrborn, C. G., Lippman, S. M. (2005). Implications of the Prostate Cancer Prevention Trial: A Decision Analysis Model of Survival Outcomes. JCO 23: 1911-1920 [Abstract] [Full Text]  
• Sesso, H. D., Chen, R. S., L'Italien, G. J., Lapuerta, P., Lee, W. C., Glynn, R. J. (2003). Blood Pressure Lowering and Life Expectancy Based on a Markov Model of Cardiovascular Events. Hypertension 42: 885-890 [Abstract] [Full Text]  
• Goldie, S. J. (2003). Chapter 15: Public Health Policy and Cost-Effectiveness Analysis. J Natl Cancer Inst Monogr 2003: 102-110 [Abstract] [Full Text]  
• Goldie, S. J., Kuntz, K. M. (2003). A Potential Error in Evaluating Cancer Screening: A Comparison of 2 Approaches for Modeling Underlying Disease Progression. Med Decis Making 23: 232-241 [Abstract]  
• Siebert, U, Sroczynski, G, Rossol, S, Wasem, J, Ravens-Sieberer, U, Kurth, B M, Manns, M P, McHutchison, J G, Wong, J B (2003). Cost effectiveness of peginterferon {alpha}-2b plus ribavirin versus interferon {alpha}-2b plus ribavirin for initial treatment of chronic hepatitis C. Gut 52: 425-432 [Abstract] [Full Text]  
• Knoll, G. A., Nichol, G. (2003). Dialysis, Kidney Transplantation, or Pancreas Transplantation for Patients with Diabetes Mellitus and Renal Failure: A Decision Analysis of Treatment Options. J. Am. Soc. Nephrol. 14: 500-515 [Abstract] [Full Text]  
• Charlson, M. E., Allegrante, J. P., McKinley, P. S., Peterson, J. C., Boutin-Foster, C., Ogedegbe, G., Young, C. R. (2002). Improving health behaviors and outcomes after angioplasty: using economic theory to inform intervention. Health Educ Res 17: 606-618 [Abstract] [Full Text]  
• Kajbaf, S., Nichol, G., Zimmerman, D. (2002). Cancer screening and life expectancy of Canadian patients with kidney failure. Nephrol Dial Transplant 17: 1786-1789 [Abstract] [Full Text]  
• Col, N. F., Goldberg, R. J., Orr, R. K., Erban, J. K., Fortin, J. M., Chlebowski, R. T. (2002). Survival Impact of Tamoxifen Use for Breast Cancer Risk Reduction: Projections from a Patient-Specific Markov Model. Med Decis Making 22: 386-393 [Abstract]  
• Pepper, P. V., Owens, D. K. (2002). Cost-Effectiveness of the Pneumococcal Vaccine in Healthy Younger Adults. Med Decis Making 22: S45-S57 [Abstract]  
• Mark, D. B., Hlatky, M. A. (2002). Medical Economics and the Assessment of Value in Cardiovascular Medicine: Part I. Circulation 106: 516-520 [Full Text]  
• Blake, G. J., Ridker, P. M., Kuntz, K. M. (2002). Projected life-expectancy gains with statin therapy for individuals with elevated c-reactive protein levels. J Am Coll Cardiol 40: 49-55 [Abstract] [Full Text]  
• Lau, E. W., Ng, G. A. (2002). Visual Illusions Created by Survival Curves and the Need to Avoid Potential Misinterpretation. Med Decis Making 22: 238-244 [Abstract]  
• Blackhouse, G., Briggs, A. H., O'Brien, B. J. (2002). A Note on the Estimation of Confidence Intervals for Cost-Effectiveness When Costs and Effects Are Censored. Med Decis Making 22: 173-177 [Abstract]  
• Jarvik, J. G. (2002). Study Design for the New Millennium: Changing How We Perform Research and Practice Medicine. Radiology 222: 593-594 [Full Text]  
• Ribstein, J., Du Cailar, G., Zanchetti, A. (2002). Cardiac and renal damage in the elderly hypertensive. Journal of Renin-Angiotensin-Aldosterone System 3: S16-S24  
• van den Akker-van Marle, M. E., van Ballegooijen, M., van Oortmarssen, G. J., Boer, R., Habbema, J. D. F. (2002). Cost-Effectiveness of Cervical Cancer Screening: Comparison of Screening Policies. JNCI J Natl Cancer Inst 94: 193-204 [Abstract] [Full Text]  
• Lewis, J. D., Brown, A., Localio, A. R., Schwartz, J. S. (2002). Initial Evaluation of Rectal Bleeding in Young Persons: A Cost-Effectiveness Analysis. ANN INTERN MED 136: 99-110 [Abstract] [Full Text]  
• Hershman, D., Sundararajan, V., Jacobson, J. S., Heitjan, D. F., Neugut, A. I., Grann, V. R. (2002). Outcomes of Tamoxifen Chemoprevention for Breast Cancer in Very High-Risk Women: A Cost-Effectiveness Analysis. JCO 20: 9-16 [Abstract] [Full Text]  
• Llovet, J M, Mas, X, Aponte, J J, Fuster, J, Navasa, M, Christensen, E, Rodes, J, Bruix, J (2002). Cost effectiveness of adjuvant therapy for hepatocellular carcinoma during the waiting list for liver transplantation. Gut 50: 123-128 [Abstract] [Full Text]  
• Kessler, K. M. (2001). Physical Activity and Cardiovascular Risk in Diabetic Women. ANN INTERN MED 135: 930-931 [Full Text]  
• Neilipovitz, D. T., Bryson, G. L., Nichol, G. (2001). The Effect of Perioperative Aspirin Therapy in Peripheral Vascular Surgery: A Decision Analysis. Anesth. Analg. 93: 573-580 [Abstract] [Full Text]  
• Messori, A., Trippoli, S., Vaiani, M., Laurence, J., Freedberg, K. A., Losina, E., Goldie, S. J. (2001). The Cost Effectiveness of Antiretroviral Therapy for HIV Disease. NEJM 345: 68-69 [Full Text]  
• Marchetti, M., Quaglini, S., Barosi, G. (2001). Cost-effectiveness of screening and extended anticoagulation for carriers of both factor V Leiden and prothrombin G20210A. QJM 94: 365-372 [Abstract] [Full Text]  
• Freedberg, K. A., Losina, E., Weinstein, M. C., Paltiel, A. D., Cohen, C. J., Seage, G. R., Craven, D. E., Zhang, H., Kimmel, A. D., Goldie, S. J. (2001). The Cost Effectiveness of Combination Antiretroviral Therapy for HIV Disease. NEJM 344: 824-831 [Abstract] [Full Text]  
• O'Brien, B. J., Connolly, S. J., Goeree, R., Blackhouse, G., Willan, A., Yee, R., Roberts, R. S., Gent, M. (2001). Cost-Effectiveness of the Implantable Cardioverter-Defibrillator : Results From the Canadian Implantable Defibrillator Study (CIDS). Circulation 103: 1416-1421 [Abstract] [Full Text]  
• Bolondi, L, Sofia, S, Siringo, S, Gaiani, S, Casali, A, Zironi, G, Piscaglia, F, Gramantieri, L, Zanetti, M, Sherman, M (2001). Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: a cost effectiveness analysis. Gut 48: 251-259 [Abstract] [Full Text]  
• Karlawish, J. H. T., Klocinski, J. L., Merz, J., Clark, C. M., Asch, D. A. (2000). Caregivers' preferences for the treatment of patients with Alzheimer's disease. Neurology 55: 1008-1014 [Abstract] [Full Text]  
• Palmer, A. J., Neeser, K., Weiss, C., Brandt, A., Comte, S., Fox, M. (2000). THE LONG-TERM COST-EFFECTIVENESS OF IMPROVING ALCOHOL ABSTINENCE WITH ADJUVANT ACAMPROSATE. Alcohol Alcohol 35: 478-492 [Abstract] [Full Text]  
• Mandelblatt, J., Yabroff, K. R., Lawrence, W., Yi, B., Orosz, G., Bloom, H. G., Schecther, C. B., Extermann, M., Balducci, L., Satadano, W., Fox, S., Silliman, R. A., Fahs, M. C., Muening, P., for the Research on Breast Cancer in Older Women C, , Rozenberg, S., Ham, H., Liebens, F., Seidenwurm, D., Breslau, J., Kerlikowske, K., Phillips, K. A., Cummings, S. R., Salzmann, P., Cauley, J. A. (2000). Screening Mammography in Elderly Women. JAMA 283: 3202-3204 [Full Text]  
• Miller, L.-A., Singer, M. E., Swanson, G. P., Schrag, D., Kuntz, K. M., Garber, J. E., Weeks, J. C. (2000). Benefit of Prophylactic Mastectomy for Women With BRCA1 or BRCA2 Mutations. JAMA 283: 3070-3072 [Full Text]  
• Bryant, J., Clegg, A., Milne, R., Richards, R., Burls, A., Payne, N., Ellis, S. J, Forbes, R. B, Swingler, R. J (2000). Cost utility of drugs for multiple sclerosis. BMJ 320: 1474-1474 [Full Text]  
• Rose, D. N. (2000). Benefits of Screening for Latent Mycobacterium tuberculosis Infection. Arch Intern Med 160: 1513-1521 [Abstract] [Full Text]  
• Schrag, D., Kuntz, K. M., Garber, J. E., Weeks, J. C. (2000). Life Expectancy Gains From Cancer Prevention Strategies for Women With Breast Cancer and BRCA1 or BRCA2 Mutations. JAMA 283: 617-624 [Abstract] [Full Text]  
• Steyerberg, E. W., Kallewaard, M., Van Der Graaf, Y., Van Herwerden, L. A., Habbema, J.D. F. (2000). Decision Analyses for Prophylactic Replacement of the Bjork-Shiley Convexo-concave Heart Valve:: An Evaluation of Assumptions and Estimates. Med Decis Making 20: 20-32 [Abstract]  
• Woolf, S. H. (1999). The Need for Perspective in Evidence-Based Medicine. JAMA 282: 2358-2365 [Abstract] [Full Text]  
• Kuntz, K. M., Tsevat, J., Weinstein, M. C., Goldman, L. (1999). Expert Panel vs Decision-Analysis Recommendations for Postdischarge Coronary Angiography After Myocardial Infarction. JAMA 282: 2246-2251 [Abstract] [Full Text]  
• Kerlikowske, K., Salzmann, P., Phillips, K. A., Cauley, J. A., Cummings, S. R. (1999). Continuing Screening Mammography in Women Aged 70 to 79 Years: Impact on Life Expectancy and Cost-effectiveness. JAMA 282: 2156-2163 [Abstract] [Full Text]  
• Sendi, P. P., Craig, B. A., Meier, G., Pfluger, D., Gafni, A., Opravil, M., Battegay, M., Bucher, H. C. (1999). Cost-effectiveness of azithromycin for preventing Mycobacterium avium complex infection in HIV-positive patients in the era of highly active antiretroviral therapy. J Antimicrob Chemother 44: 811-817 [Abstract] [Full Text]  
• Ng, A. K., Weeks, J. C., Mauch, P. M., Kuntz, K. M. (1999). Decision Analysis on Alternative Treatment Strategies for Favorable-Prognosis, Early-Stage Hodgkin's Disease. JCO 17: 3577-3585 [Abstract] [Full Text]  
• Sarasin, F.P. (1999). Decision analysis and the implementation of evidence-based medicine. QJM 92: 669-671 [Abstract] [Full Text]  
• The Magnetic Resonance Angiography in Relatives of, (1999). Risks and Benefits of Screening for Intracranial Aneurysms in First-Degree Relatives of Patients with Sporadic Subarachnoid Hemorrhage. NEJM 341: 1344-1350 [Abstract] [Full Text]  
• Holland, R. R., Ellis, C. A., Geller, B. M., Plante, D. A., Secker-Walker, R. H. (1999). Life Expectancy Estimation with Breast Cancer: Bias of the Declining Exponential Function and an Alternative to Its Use. Med Decis Making 19: 385-393 [Abstract]  
• Col, N. F., Pauker, S. G., Goldberg, R. J., Eckman, M. H., Orr, R. K., Ross, E. M., Wong, J. B. (1999). Individualizing Therapy to Prevent Long-term Consequences of Estrogen Deficiency in Postmenopausal Women. Arch Intern Med 159: 1458-1466 [Abstract] [Full Text]  
• Fuster, V. (1999). Epidemic of Cardiovascular Disease and Stroke: The Three Main Challenges : Presented at the 71st Scientific Sessions of the American Heart AssociationDallas, Texas. Circulation 99: 1132-1137 [Full Text]  
• Roizen, M. F., Roach, K., Messori, A., Trippoli, S., Tendi, E., Weinstein, M. C., Wright, J. C. (1998). Gains in Life Expectancy from Medical Interventions. NEJM 339: 1943-1944 [Full Text]  
• Wong, J. B., Bennett, W. G., Koff, R. S., Pauker, S. G. (1998). Pretreatment Evaluation of Chronic Hepatitis C: Risks, Benefits, and Costs. JAMA 280: 2088-2093 [Abstract] [Full Text]  
• Detsky, A. S., Redelmeier, D. A. (1998). Measuring Health Outcomes -- Putting Gains into Perspective. NEJM 339: 402-404 [Full Text]  
• Hunink, M.G. M., Krestin, G. P. (2002). Study Design for Concurrent Development, Assessment, and Implementation of New Diagnostic Imaging Technology. Radiology 222: 604-614 [Abstract] [Full Text]